Home › Immune System and Disorders › NCT04784364
Biologics And Clinical Immunology Cohort at Sinai
Who can join
Ages 12 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Age 12 years and up. * Able to provide informed consent. * Medical care at Mount Sinai. * Receiving a biologic medication or immune modulator at Mount Sinai, or considered an appropriate negative control or comparison participant by the study team.
About the study
The study team plans to establish a bioregistry of patients receiving biologic therapy as part of their standard treatment at the Mount Sinai Therapeutic Infusion Center and affiliated practices. The study team will to apply state-of-the-art approaches to assessing and predicting immunological and clinical responses associated with these standards and prescribed treatments. The approach is twofold. The first component is to establish a robust and flexible biorepository and database that includes demographic, immunologic, exposure and clinical records, and can facilitate research across disciplines, and across other registries affiliated with Mount Sinai. The second component is to address specific key research questions focused on using novel diagnostics to increase the effectiveness of biologic treatment. Most patients will be recruited from the Mount Sinai Therapeutic Infusion Center (TIC), although others receiving infusions elsewhere or at home will be recruited from outpatient Sinai affiliated clinical practices.
Sponsor: Icahn School of Medicine at Mount Sinai · Participants: 800 · Started: Mar 3, 2021
Contact the study team
- Sarah Alvi · Phone: 212-659-9416
- Sonia Parmar · Phone: 973-944-8221
Official record on ClinicalTrials.gov — NCT04784364
Locations in the U.S.
| New York | Mount Sinai, New York |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.